Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockers have drawn attention to be one of the early immune checkpoint signal processes within the tumor’s microenvironment because they significantly reduced tumor activity and were used in clinical settings [13]. Here, CTLA4 is linked to neoplasm.